The estimated Net Worth of Misbah Tahir is at least $1.91 millió dollars as of 14 June 2024. Mr. Tahir owns over 1,570 units of IGM Biosciences stock worth over $1,043,076 and over the last 5 years he sold IGMS stock worth over $276,263. In addition, he makes $588,979 as Chief Financial Officer at IGM Biosciences.
Misbah has made over 10 trades of the IGM Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,570 units of IGMS stock worth $11,901 on 14 June 2024.
The largest trade he's ever made was selling 6,084 units of IGM Biosciences stock on 16 December 2022 worth over $119,368. On average, Misbah trades about 1,127 units every 58 days since 2020. As of 14 June 2024 he still owns at least 88,848 units of IGM Biosciences stock.
You can see the complete history of Mr. Tahir stock trades at the bottom of the page.
Misbah Tahir CPA serves as Chief Financial Officer of the Company. Mr. Tahir worked at Dermira, a biotechnology company, where he served as Vice President, Head of Finance from March 2016 to December 2018, Senior Director, Head of Finance from January 2015 to March 2016, and Senior Director, Finance from January 2014 to December 2014. Prior to joining Dermira, he held finance leadership positions at various biotechnology companies, including Onyx Pharmaceuticals, Human Genome Sciences and Amgen. Mr. Tahir began his career as a management consultant at the consulting firm of Oliver Wyman, formerly Mercer Management Consulting. He received a B.A. in International Relations from the University of Pennsylvania and an M.B.A. from the University of Michigan Business School. Mr. Tahir is a certified public accountant, inactive, in the state of California.
As the Chief Financial Officer of IGM Biosciences, the total compensation of Misbah Tahir at IGM Biosciences is $588,979. There are 7 executives at IGM Biosciences getting paid more, with Fred M. Schwarzer J.D. having the highest compensation of $926,901.
Misbah Tahir is 45, he's been the Chief Financial Officer of IGM Biosciences since 2019. There are 17 older and 2 younger executives at IGM Biosciences. The oldest executive at IGM Biosciences, Inc. is Michael Loberg, 72, who is the Independent Chairman of the Board.
Misbah's mailing address filed with the SEC is C/O IGM BIOSCIENCES, INC., 325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW, CA, 94043.
Over the last 5 years, insiders at IGM Biosciences have traded over $2,263,330 worth of IGM Biosciences stock and bought 10,358,723 units worth $195,788,133 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Group, Llc Green Jeremy Red... és Bros. Advisors Lp667, L.P.B.... On average, IGM Biosciences executives and independent directors trade stock every 13 days with the average trade being worth of $942,182. The most recent stock trade was executed by Julie Hambleton on 25 July 2024, trading 15,132 units of IGMS stock currently worth $21,033.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
IGM Biosciences executives and other stock owners filed with the SEC include: